A federal overhaul of the 340B drug-discount program, effective January 2027, will shift discounts from upfront price cuts to later rebates, creating a financing gap for hospitals. This change may increase borrowing demand from hospitals, especially those serving low-income patients, benefiting banks that already provide credit lines to these institutions. Major banks like U.S. Bancorp and PNC Financial Services are positioned to profit from increased lending and fees. However, legal challenges and the program's uncertain launch could delay or block these changes, making this a potential but not guaranteed opportunity for investors.
US Bancorp trades at USD 58.00, down 1.84% as of Oct 21, 2026 17:02 WIB on Pluang. PNC Financial Services is nearly flat at USD 220.90 with a slight 0.04% decrease. Bank of America shows a small gain of 0.22%, priced at USD 50.75. These banks could see lending growth if the 340B program changes increase hospital borrowing needs.
PNC Financial Services and U.S. Bancorp both posted solid Q3 results, with PNC repurchasing about $560 million of stock while USB did not buy back shares as it focuses on rebuilding its capital ratio ahead of stricter regulations. PNC's loan growth i...
U.S. Bancorp received a buy rating upgrade following its strong Q3 performance, which included record net revenue, 5.6% year-over-year net interest income growth, 14.9% fee growth, and 8% loan growth. The bank's return on equity and operating margins...
